ACADIA Pharmaceuticals (NASDAQ:ACAD) Given "Hold (C)" Rating at Weiss Ratings

Key Points

• ACADIA Pharmaceuticals has received a "hold (C)" rating from Weiss Ratings, with various other analysts issuing mixed ratings, including several "buy" ratings and one "sell."
• As of Tuesday, shares of ACAD traded at $20.03, down 0.1%, with a one-year price range between $13.40 and $26.65, reflecting a market capitalization of $3.38 billion.
• Insider trading activity includes director Elizabeth A. Garofalo selling 1,600 shares and EVP Mark C. Schneyer selling 3,498 shares, indicating insider profit-taking amid stock performance changes.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report)'s stock had its "hold (c)" rating reissued by investment analysts at Weiss Ratings in a research note issued to investors on Tuesday,Weiss Ratings reports.

A number of other equities analysts have also recently issued reports on the stock. Needham & Company LLC reduced their price objective on shares of ACADIA Pharmaceuticals from $30.00 to $28.00 and set a "buy" rating on the stock in a research note on Wednesday, September 24th. UBS Group raised their price target on ACADIA Pharmaceuticals from $36.00 to $39.00 and gave the stock a "buy" rating in a research report on Tuesday, September 9th. Cowen restated a "buy" rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, September 11th. TD Cowen boosted their target price on ACADIA Pharmaceuticals from $35.00 to $39.00 and gave the stock a "buy" rating in a research report on Thursday, September 11th. Finally, Citigroup reissued an "outperform" rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $29.12.

ACADIA Pharmaceuticals Trading Down 0.1%

Shares of ACAD traded down $0.03 during mid-day trading on Tuesday, hitting $20.03. 1,329,206 shares of the company traded hands, compared to its average volume of 2,182,490. ACADIA Pharmaceuticals has a one year low of $13.40 and a one year high of $26.65. The business has a 50-day moving average of $23.86 and a 200 day moving average of $21.03. The stock has a market capitalization of $3.38 billion, a price-to-earnings ratio of 15.06, a PEG ratio of 7.05 and a beta of 0.75.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.16 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.02. The firm had revenue of $264.57 million for the quarter, compared to analyst estimates of $263.07 million. ACADIA Pharmaceuticals had a return on equity of 14.69% and a net margin of 21.80%.The business's quarterly revenue was up 9.4% compared to the same quarter last year. During the same period last year, the company earned $0.20 EPS. As a group, analysts anticipate that ACADIA Pharmaceuticals will post 0.7 earnings per share for the current year.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, Director Elizabeth A. Garofalo sold 1,600 shares of the business's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $25.98, for a total value of $41,568.00. Following the sale, the director directly owned 25,382 shares in the company, valued at $659,424.36. The trade was a 5.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Mark C. Schneyer sold 3,498 shares of the business's stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $23.65, for a total value of $82,727.70. Following the completion of the sale, the executive vice president owned 43,447 shares in the company, valued at $1,027,521.55. The trade was a 7.45% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,098 shares of company stock worth $678,256 over the last ninety days. 28.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ACAD. GAMMA Investing LLC lifted its position in ACADIA Pharmaceuticals by 11,981.0% during the 1st quarter. GAMMA Investing LLC now owns 58,351 shares of the biopharmaceutical company's stock worth $969,000 after buying an additional 57,868 shares in the last quarter. Yousif Capital Management LLC bought a new stake in ACADIA Pharmaceuticals during the first quarter worth about $764,000. Exchange Traded Concepts LLC acquired a new position in ACADIA Pharmaceuticals during the first quarter valued at approximately $29,000. State of Alaska Department of Revenue bought a new position in ACADIA Pharmaceuticals in the first quarter valued at approximately $1,133,000. Finally, Oppenheimer Asset Management Inc. increased its position in shares of ACADIA Pharmaceuticals by 10.9% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 35,864 shares of the biopharmaceutical company's stock worth $596,000 after purchasing an additional 3,535 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company's stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.